Figure 5.

Cisplatin-surviving cells have high mitochondrial density and ROS content, both of which are reduced by ZA. (A) Representative images of mitochondrial staining of cancer cells treated with cisplatin or cisplatin + ZA are demonstrated. (B) Representative flow-cytometry graphs and (C) quantification of four independent experiments demonstrated the augmentation of mitochondrial density after cisplatin and the partial declining effect of ZA. (D, E) ROS content of cisplatin-survived cells is increased and is significantly diminished after ZA administration. (F) The effect of ZA in declining ROS in cisplatin-treated cells is observed both in diploid and polyploid sub-populations. *p- value < 0.05; ** p- value < 0.01; error bars: mean ± SEM.